Irving Ford

Irving has over 28 years of QA/QC experience in pharmaceutical/biotechnology and cell/gene therapies industries. Prior to joining Celgene, Irving was a significant contributor for activities supporting the commercial approval of Novartis’ CAR T product Kymriah. Irving is an active member of PDA and recently served on the committee for the 2018 Global Conference on Pharmaceutical Microbiology. Irving is also a co-author for PDA’s TR for EM of Low Bioburden Facilities.